Vicarius Pharma

Sep 21, 2021

Fusion Pharmaceuticals appoints new senior vice president, business development Dr. Hoffman has experience in the biotechnology industry, most recently acting as chief business officer at Vicarius Pharma. September 21, 2021  by CM Staff HAMILTON and BOSTON — Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development. “The field of radiopharmaceuticals is experiencing a resurgence of interest and excitement, and Fusion is well-positioned with a platform to create differentiated targeted alpha therapies (TATs) from a wide range of targeting molecules, including antibodies and small molecules,” said Fusion Chief Executive Officer John Valliant, Ph.D. “With the expansion of our pipeline of TATs through both proprietary and partnered programs, expanding our leadership team is a key part of our strategy to meet the growth opportunities in front of us. To that end, Eric brings to our team deep business development and corporate strategy experience, combined with a scientific and finance background.” Dr. Hoffman has experience in the biotechnology industry, most recently acting as chief business officer at Vicarius Pharma, where he was a part of business development efforts to in-license European commercialization rights for oncology and other products. Prior to Vicarius, he was chief business officer of Genocea Biosciences where he led business development, alliance management and commercial operations. Prior to Genocea, he was vice president of corporate and business development and executive director of investor relations and corporate communications at Idenix Pharmaceuticals until the acquisition by Merck & Co. Dr. Hoffman was previously director of corporate and business development and director of investor relations at Biogen Idec. He also previously worked for more than five years on Wall Street as a biotechnology equity analyst at JPMorgan Securities and a biotechnology research associate at Bear Stearns International. Dr. Hoffman was a post-doctoral research associate in the Department of Immunobiology at King’s College in London. He holds a Ph.D. in molecular, cellular and developmental biology with a focus on T cell immunology from Yale University, and a B.S. in biology from Trinity University. Advertisement